Amicus Therapeutics (FOLD) received an analyst upgrade today from Needham. The analyst, Gil Blum, has changed the rating from Hold to Buy, reflecting positive sentiment towards the company's prospects. Additionally, a new price target of $14 has been established, although no prior price target was provided.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.